País: Armênia
Língua: inglês
Origem: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
sodium chloride, potassium chloride, calcium chloride
Liqvor CJSC
B05BB01
sodium chloride, potassium chloride, calcium chloride
8,6mg/ml+ 0,3mg/ml+ 0,49mg/ml
solution for infusion
250ml, 500ml and 1000ml plastic pack
Prescription
Registered
2018-07-11
1 SUMMURY OF PRODUCT CHARACTERISTICS 1. NAME OF MEDICINAL PRODUCT: Ringer`s injection INN: Sodium chloride, Potassium chloride, Calcium chloride 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Sodium chloride - 8,6 g (Eur. Ph., Monograph 0193) Potassium chloride - 0,3 g (Eur. Ph., Monograph 0185) Calcium chloride 6Н 2 О - 0,49 g (Eur. Ph., Monograph 0707) Water for injection - до 1 L (Eur. Ph., Monograph 0169) DESCRIPTION: Clear colorless solution. 3. PHARMACEUTICAL FORM: solution for infusion 4. CLINICAL PARTICULARS 4.1 INDICATIONS FOR USE Dehydration of different genesis, hyponatremia, during and after operations to maintain the volume of plasma, in acute circulatory disorders, accompanied by dehydration. 4.2 DOSAGE AND ADMINISTRATION Ringer`s injection must be administrated by intravenous at a rate infusion at a rate of 4 - 10 ml / kg / hour (up to 3 liters per day). The dosage is individual, depending on the deficiency of water and electrolytes. Prolonged administration of large doses of the drug is preferably to conduct under the control of laboratory tests. 4.3 CONTRAINDICATIONS Hypersensitivity to the drug components, decompensated heart failure, pulmonary edema, brain edema, oliguria, anuria, acidosis, hypervolemia, hyperchloremia, 2 hypercalcemia, hypernatremia, concomitant therapy with corticosteroids. With caution - heart failure, hypertension, hepatic or renal dysfunction. 4.4 SPECIAL WARNING At a long-term treatment it is necessary to control the plasma electrolytes and water balance. Due to high levels of chloride ions do not recommend the long-term use of the drug. 4.5 DRUG INTERACTION It is possible the increasing of the sodium retention in the organism at simultaneous use of the following drugs: non-steroidal anti-inflammatory drugs, androgens, anabolic hormones, estrogens, corticotropin, mineralocorticoids, vasodilators or ganglionic blockers. The simultaneous use with potassium-sparing diuretics, ACE inhibitors and potassium therapy increases the risk of hyperkalemia. The combination with cardi Leia o documento completo